|View printer-friendly version|
Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
- Cowen and Company’s 37th Annual
Health Care Conferenceon Tuesday, March 7, 2017, at 9:20 a.m. Eastern Timein Boston.
- Oppenheimer’s 27th Annual Healthcare Conference on
Wednesday, March 22, 2017, at 1:35 p.m. Eastern Timein New York.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Ana Kapor Portola Pharmaceuticalsir@portola.com Media Contact: Julie Normart Pure Communicationsjnormart@purecommunications.com 415.946.1087